Revvity, Inc. (RVTY)

NYSE • Healthcare

$158.77

+$1.4 (+0.9%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$156.35

Previous Close$158.77

Day Range$152.73 - $159.05

Avg. Volume (3M)1.8M

Market Cap$17.7B

P/E Ratio75.6

52 Week Range

$81.22$166.25

Metrics Over Time

Where the Money Goes

Q3 2026

Revenueeverything earned$729.6M100%

Gross Profitminus cost of goods$416.8M57%

Operating Incomeminus R&D and overhead$89.3M12%

Net Incomeminus taxes and the rest$51.8M7%

In plain terms: out of every $100 in revenue, Revvity, Inc. keeps $7 as net profit.

Fundamentals & Financials

Revenue (TTM)

$2.9B

Net Income (TTM)

$237.5M

EPS (TTM)

$2.1

ROA (TTM)

1.97%

Current Ratio

1.8

Dividend Yield

0.062%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+3.5%Q3 2025$1.18

+3.5%Q4 2025$1.18

+8.3%Q1 2026$1.7

+3.9%Q2 2026$1.06

+16.5%Q3 2026$1.41

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +16.5%

Revvity beat on adjusted EPS in the second fiscal quarter of 2026, reporting on Aug. 4 based on preliminary results, as adjusted EPS of $1.41 topped the $1.21 estimate by 16.5%. Revenue rose about 1% to roughly $729.7 million, with operating income at about $89.3 million, operating margin near 12%, and gross margin around 57%; net income came to about $51.8 million, down about 6% from about $55.2 million a year earlier. The company generated operating cash flow of about $195.6 million, repurchased $16.0 million of stock, and paid $7.8 million in dividends. Consensus for the next period calls for EPS of $1.30.

Next report — what to expect

Revvity, Inc. (RVTY) reports on October 26, 2026. Wall Street is expecting consensus EPS of $1.28 on consensus revenue of $694.4 million. For trailing context, revenue grew +1.3% year over year last quarter. Revvity has beaten EPS in 8 of 8 most recent quarters, making EPS versus expectations a key watch item.

View full earnings history

About Revvity, Inc.

Revvity, Inc. (NYSE: RVTY) develops diagnostic and life sciences tools, software, and services for healthcare and research markets worldwide. The company, which operates in medical diagnostics and research, generated $2.9 billion of revenue in FY2025. It sells across discovery, analytical, and testing workflows rather than through a single product line.

Name

Revvity, Inc.

CEO

Prahlad R. Singh

Website

www.revvity.com

Industry

Healthcare

Year Founded

1937

Employees

11,000

Today's Snapshot

AI-generated

The day ended with RVTY 0.9% higher at 158.73, outperforming a weaker sector. Volume was about two-thirds of its usual level.

Trading Volume

Below 10d avg (1.6M)

903.4K

vs S&P 500 Today

Outperforming Market

+1.44%

Updated: October 23, 2026 at 20:11 UTC

RVTY Headlines

Healthcare stocks fall after weak US jobs data

March 6, 2026

3 min read

View All News

Technical Indicators

5 Buy3 Neutral0 Sell

RVTY displays a robust technical profile with a clear trending backdrop and broad moving-average support while momentum reads as constructive. The stock trades well above its short-, medium- and 200-day averages, ADX signals a strong trend, and on-balance volume is positive, reinforcing the advance. RSI is healthy rather than extreme and MACD/momentum metrics show continued buying interest, while ATR indicates moderate volatility and the price sits near the classic pivot. Technical takeaway: strong buy underpinned by a powerful trend and aligned moving averages with confirming volume.

All signals